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Objective: The GOLD guidelines suggest that the presence of a post-bronchodilator forced 
expiratory volume in one second (FEV1)   80% of the predicted value in combination with a 
FEV1/forced vital capacity (FVC)   70% conﬁ  rms the diagnosis of COPD. Limited data exist 
regarding the accuracy of these criteria to distinguish between COPD and asthma. The aim of 
this study therefore was to investigate the diagnostic value of post-bronchodilator lung function 
parameters in obstructive lung disease.
Methods: The pulmonary function tests of 43 (22 = COPD, 21 = asthma) patients with similar 
baseline characteristics were evaluated (baseline FEV1 were 55.7% + 7.6%, and 59.3% + 8.4% 
predicted for COPD and asthma, respectively). Bronchodilator responsiveness (BDR) was 
calculated according to three recognized pulmonary function test criteria.
Results: The first criteria, post-bronchodilator FEV1   80% of the predicted value in 
combination with a post-bronchodilator FEV1/FVC ratio of  70%, had an accuracy of 70% to 
diagnose COPD. This combination was very sensitive (100%) in diagnosing COPD, but it was 
not speciﬁ  c (38%). The second BDR criteria, deﬁ  ned as an increase of  12% and 200 mL of 
initial FEV1 and criterion number 3, an increase of  9% of predicted FEV1, were less sensitive 
(55% and 59%, respectively), but more speciﬁ  c (81% and 76% respectively) to diagnose COPD. 
Our ﬁ  ndings suggest that the current recommended spirometric indices are not optimal in 
differentiating between COPD and asthma.
Keywords: obstructive lung disease, diagnosis, post-bronchodilator pulmonary 
function test
Introduction
COPD and asthma are common conditions and their worldwide prevalence is expected 
to increase over the next twenty years (Murray and Lopez 1997). Although the two 
diseases share many clinical features, there are important clinical and pathological 
differences inﬂ  uencing choice of medication and long-term aims of management 
(Jeffrey 1998; Celli 2000; Fabri et al 2003).
The degree of reversibility following bronchodilator administration has played a 
pivotal role in the evaluation of obstructive lung disease, thereby inﬂ  uencing drug choice 
and patterns of care (Dow 1999). In addition to the clinical importance, bronchodilator 
testing can have regulatory importance as European regulators now require that COPD 
patients included in clinical trials meet the ERS deﬁ  nition of irreversible disease 
(Calverley et al 2003). Signiﬁ  cant reversibility is denoted by the American Thoracic 
Society (ATS) as a change of  12% of the baseline forced expiratory volume in one 
second (FEV1) if this also exceeds 200 mL, while the European Respiratory Society 
(ERS) recommends a change of  9% of the predicted FEV1 (American Thoracic 
Society 1991; Quanjer et al 1993). The numerous ways of expressing BDR have been International Journal of COPD 2008:3(4) 694
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challenged repeatedly (Weir and Burge 1991; Brand et al 
1992; Dompeling et al 1992). Although historically used 
to diagnose asthma, none of these current deﬁ  nitions are 
sensitive or sufﬁ  ciently speciﬁ  c to differentiate asthma from 
COPD purely on spirometric grounds (Meslier et al 1989; 
Bran et al 1992; Quedrelli et al 1999b).
The GOLD guidelines suggest that the diagnosis of 
COPD should be conﬁ  rmed by spirometry. The presence of 
a post-bronchodilator FEV1   80% of the predicted value in 
combination with a FEV1/FVC   70% conﬁ  rms the presence 
of airﬂ  ow limitation that is not fully reversible (Pauwels et al 
2001). The usefulness of these post-bronchodilator spiromet-
ric variables as diagnostic criteria in BDR testing has to our 
knowledge not been assessed systematically in patients with 
obstructive lung disease.
The aim of our study, therefore, was to investigate the 
accuracy of a number of spirometric criteria used to express 
the BDR and assess how well they are able to distinguish 
between COPD and asthma in our study population. We 
hypothesized that the post-bronchodilator FEV1   80% of the 
predicted in combination with a FEV1/FVC ratio of   70% 
would be more sensitive and speciﬁ  c to distinguish COPD 
from asthma than the use of ATS and ERS BDR criteria in 
moderately severe obstructive lung disease.
Methods
Subjects
Consecutive subjects with airways obstruction, meeting 
inclusion criteria as speciﬁ  ed below, were prospectively 
recruited. All participants had to be able to perform techni-
cally acceptable pulmonary function tests. Medical histories, 
including speciﬁ  c respiratory symptoms, were obtained in a 
standardized manner. Inclusion criteria for the COPD group 
were a smoking history of more than ten pack years, asso-
ciated with chronic cough and/or sputum production with 
an onset of symptoms after 40 years of age. An exclusion 
criterion for the COPD group was a history of asthma. The 
asthma group had to be older than 40 years of age with recur-
rent episodes of wheezing, breathlessness, chest tightness, 
and coughing, particularly at night or in the early morning. 
In addition, these subjects had to be ex- or nonsmokers with 
a less than ten pack year history. All patients had to be clini-
cally stable with no respiratory exacerbations for six weeks 
prior to inclusion in the study and no changes in chronic 
medication during this period. Respiratory exacerbations 
were deﬁ  ned as an increase in breathlessness, sputum volume 
or sputum purulence from baseline requiring treatment with 
prednisone and/or antibiotics.
To ensure comparable baseline characteristics, we 
included only patients with a pre-bronchodilator FEV1% 
predicted of between 40% and 70% as well as a FEV1/FVC 
ratio between 45% and 65%, as the population of moderately 
severe obstructive lung disease poses the greatest challenge 
in differentiating COPD from asthma.
Study design
All subjects signed written informed consent for participation 
in the study. The local ethics committee approved the study. 
Bronchodilator treatment was withdrawn prior to pulmonary 
function testing according to standard practice (immediate 
release theophylline: 24 hours, long acting β2-agonist: 
12 hours, short acting β2-agonist: 6 hours and short acting 
anticholinergic: 8 hours).
Procedures
A qualiﬁ  ed pulmonary technologist conducted maximal in-and 
expiratory ﬂ  ow volume curves with subjects seated before 
(‘pre’) and after (‘post’) administration of 400 μg salbutamol. 
The medication was given via a metered dose inhaler with 
a large volume spacer (Volumatic, GlaxoSmithKline). ATS 
guidelines (1994) were adhered to concerning spirometric 
assessments, calibration and equipment maintenance. All pul-
monary function measurements were made using a Jaeger 
Masterscope 4.0 spirometer (Würzburg, Germany). Predicted 
normal values were calculated as laid down by the European 
Community for Coal and Steel (ECCS). For analysis, the best 
FEV1 and forced vital capacity (FVC) were chosen regardless 
of the curve. The ‘best test’ curve was selected from the largest 
sum of FEV1 and FVC. All other lung function parameters 
selected for analysis were taken from the ‘best test’ curve.
Evaluation of bronchodilator response
Bronchodilator responsiveness (BDR) was calculated 
according to the following three criteria: 1) FEV1 post-
bronchodilator  80% predicted and FEV1/FVC ratio   70%, 2) 
FEV1 change from initial (FEV1 %Δinit: post FEV1 – pre 
FEV1/pre FEV1 × 100) less than 12% and FEV1 absolute 
change (FEV1 abs Δ: post FEV1 – pre FEV1) less than 200 mL 
(according to ATS guidelines) (American Thoracic Society 
1991) and 3) FEV1 change from predicted (FEV1 %Δpred: 
post FEV1 –pre FEV1/predicted FEV1 × 100) less than 9% 
(according to ERS guidelines) (Quanjer et al 1993).
Data analysis
Results are presented as means + standard error of mean. 
A p value of   0.05 was considered signiﬁ  cant. Descriptive International Journal of COPD 2008:3(4) 695
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group data were compared using the unpaired student t-test. 
Differences among the groups were evaluated using analysis 
of variance (ANOVA). The sensitivity and speciﬁ  city as well 
as the predictive values and accuracy of a BDR to salbutamol 
in distinguishing patients with COPD and asthma were 
calculated for the three criteria as outlined above.
Results
Subject characteristics
104 patients with COPD and 127 patients with asthma were 
evaluated consecutively. 22 COPD and 21 asthma patients 
with a baseline FEV1 of 55.7% + 7.6%, and 59.3% + 8.4% 
predicted respectively met the inclusion criteria and were 
included for further analyses.
Subject characteristics are outlined in Table 1. 
The COPD and asthma groups had comparable base-
line pre-bronchodilator pulmonary function tests and 
demographics.
All subjects were on short acting β2-agonist therapy. 
9 (41%) COPD patients were on inhaled or oral cortico-
steroids, 5 (23%) were on long acting β2-agonist therapy 
and 8 (36%) were on theophylline. All asthmatic patients 
were on inhaled steroids. No asthmatic patient was on oral 
steroids, theophylline or long acting β2-agonist therapy. 
Subgroup analysis showed that corticosteroid treatment did 
not signiﬁ  cantly inﬂ  uence bronchodilator response within 
the COPD group (p   0.07, data not shown).
Bronchodilator responses
Spirometric changes in response to salbutamol are shown in 
Table 2. After salbutamol inhalation there was a statistically 
signiﬁ  cant increase of all ﬂ  ow volume curve parameters 
in both groups. The mean responses were signiﬁ  cantly 
greater for the asthma group for all the FEV1 criteria 
(Table 2). The absolute change in FVC after bronchodilator 
administration was significantly greater in the asthma 
subjects in comparison to the COPD group (Table 2). 
The FEF50 showed a signiﬁ  cant response to salbutamol in 
the asthma patients, but not in the subjects with COPD 
(Table 2). The pre- and post-bronchodilator FEV1/FVC ratio 
remained almost the same in the COPD group, whereas in 
comparison the ratio increased signiﬁ  cantly (p = 0.003) 
Table1 Baseline pre-bronchodilator subject characteristics
COPD Asthma
Subjects n 22 21
F:M 13:9 11:10
Age yrs 52.2 (1.15) 50.1 (1.44)
Pack years 43.8 (2.9) 0
Medication
 Short  acting  β2-agonist 22 (100%) 21 (100%)
  Short acting anticholinergic 15 (68%) 6 (29%)
 Long  acting  β2-agonist 5 (23%) 0
  Long acting anticholinergic 0 0
  Inhaled corticosteroid 9 (41%) 21 (100%)
 Theophylline 8  (36%) 0
Height cm 1.64 (0.18) 1.68 (0.02)
Weight kg 69.23 (3.56) 79.61 (2.78)*
BMI kgm2 25.6 (1.25) 28.1 (0.94)
Spirometry
 FEV1 L 1.57 (0.10) 1.80 (0.10)
    %pred 55.74 (1.63) 59.29 (1.82)
  FVC L 2.82 (0.16) 3.17 (0.18)
    %pred 83.5 (1.98) 86.5 (2.74)
 FEF50 L 0.90 (0.07) 1.05 (0.06)
    %pred 21.79 (1.52) 24.45 (1.24)
 FEV1/FVC% 55.74 (0.99) 57.65 (1.16)
Abbreviations: COPD, chronic obstructive pulmonary disease; F, female; M, male; BMI, 
body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capac-
ity; FEF50, forced expiratory ﬂ  ow at 50% of FVC; %pred, percentage of predicted.
Notes: Data are presented as mean + SEM. Spirometric comparisons between groups 
were made only between % pred normal values.
*p   0.05, signiﬁ  cant difference between groups.
Table 2 Responses to 400 μg salbutamol metered dose inhaler
COPD Asthma
FEV1
%pred (post bd) 63 (1.5) 75 (2.1)**
%∆init 13 (3) 27 (3)**
%∆pred 7 (2) 15 (2)**
abs∆ L 0.185 (0.04) 0.445 (0.03)***
FVC
%pred (post bd) 90 (3) 97 (3) ns
%∆init 8 (3) 13 (2) ns
%∆pred 6 (2) 11 (2) ns
abs∆ L 0.193 (0.07) 0.375 (0.05)*
FEF50
%pred (post bd) 25 (2) 36 (2)***
%∆init 18 (6) 52 (6)**
%∆pred 4 (1) 12 (1)***
abs∆ L 0.151 (0.05) 0.492 (0.05)***
FEV1/FVC (post bd) 58 (2) 64 (1)*
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; FEF50, forced expiratory ﬂ  ow at 50% of FVC; % pred, percentage of predicted; 
%∆init, percentage change from initial; %∆pred, percentage change from predicted; 
abs∆, absolute change.
Note: Data are presented as mean + SEM
*p   0.01, p   0.001, p   0.0001, signiﬁ  cant difference in COPD versus asthma 
groups.International Journal of COPD 2008:3(4) 696
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in the asthma group (Figure 1). The post bronchodilator 
FEV1 % predicted was signiﬁ  cantly (p = 0.0002) lower in 
the COPD group (Figure 1). All COPD and 13 (62%) of 
asthma patients fulﬁ  lled the ﬁ  rst tested BDR criteria (FEV1 
post-bronchodilator  80% predicted and FEV1/FVC ratio 
 70%). 12 (55%) COPD and 4 (19%) Asthma patients had 
a positive response according to the second criteria of a BDR 
  12% and FEV1 absolute change  200 mL. The third BDR 
criteria, FEV1 change from predicted  9%, was fulﬁ  lled in 
13 (59%) COPD and 5 (24%) asthma patients. There was a 
signiﬁ  cant difference between the two groups in the FEV1 
bronchodilator response when expressed as a percentage of 
the initial value (p = 0.001) as well as for the change from 
predicted criteria ( p = 0.0003) (Figure 2).
The sensitivity, specificity, predictive values and 
accuracy of diagnosing COPD for each of the three BDR 
criteria, as deﬁ  ned above, are given in Table 3. Although 
the ﬁ  rst criteria tested (FEV1 post-bronchodilator  80% 
predicted and FEV1/FVC ratio  70%) proved to be the 
most sensitive (100%) to diagnose COPD, it was the least 
speciﬁ  c (38%) criteria to rule out asthma. The second 
(BDR   12% and FEV1 absolute change  200 mL) and 
third (FEV1 change from predicted  9%) criteria had a 
speciﬁ  city of 81% and 76% respectively with a sensitivity 
of 55% and 59% respectively.
Discussion
Although previous studies have examined the ability of 
different BDR indices to distinguish between COPD and 
asthma, the diagnostic value of the post-bronchodilator FEV1/
FVC ratio and FEV1   80% predicted have to our knowledge 
not been assessed systematically in a group of obstructive lung 
disease patients with comparable baseline lung function sever-
ity. Our data suggest that the post-bronchodilator FEV1   80% 
predicted in combination with a post-bronchodilator FEV1/
FVC ratio  70% are more sensitive in diagnosing COPD, 
but it is less speciﬁ  c than the current ATS and ERS BDR 
indices (BDR   12% and FEV1 absolute change  200 mL 
or FEV1 change from predicted  9%) (American Thoracic 
Society 1991; Quanjer et al 1993).
The usefulness of classifying patients based on their 
response to bronchodilator administration has signiﬁ  cant 
limitations (Calvery et al 2003). The evaluation of therapeutic 
efﬁ  cacy needs to be reassessed and the traditional reliance on 
an improved post-bronchodilator FEV1 has clear limitations 
(Pellegrino et al 1993; O’Donnell 2000). The use of exercise 
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Figure 1 Post bronchodilator FEV1 % predicted ()  and FEV1/FVC ratio (     ) with horizontal bars indicating conﬁ  dence limits for means at 95% conﬁ  dence interval.International Journal of COPD 2008:3(4) 697
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testing with reliable subjective measurements of dyspnea 
and quality of life has been found to be more sensitive 
to adequately predict a positive clinical response to 
bronchodilator therapy, but this comprehensive therapeutic 
assessment of bronchodilator efﬁ  cacy may not be feasible 
for many clinicians managing COPD (O’Donnell 2000). 
An additional advantage of the FEV1/FVC ﬁ  xed ratio could 
be that only one post-bronchodilator ﬂ  ow volume curve is 
required, and the need for calculation of a BDR is eliminated, 
which means that this approach would be timesaving and less 
susceptible to calculation errors.
It is known that the BDR is signiﬁ  cantly inﬂ  uenced by 
the degree of baseline impairment when expressed as a 
percentage of the initial ﬂ  ow volume curve value (Eliasson 
and Degraff 1985; Calverley et al 2003). Despite the fact that 
patients with more severe obstruction will show a greater 
improvement than patients with a higher baseline value, 
this criteria is still used at times as part of the inclusion or 
exclusion criteria for pharmaceutical trials, and it can lead 
to inaccurate clinical diagnoses affecting patient manage-
ment. Due to this well known fact we chose to include only 
patients with comparable baseline lung function impairment. 
This inclusion criterion resulted in relatively low numbers 
of patients ultimately included in the ﬁ  nal analysis and this 
could be a possible limitation of our study.
Instead of looking at degrees of reversibility that exceed 
arbitrary thresholds, a more useful feature for conﬁ  rmation 
of COPD is that the patient’s lung function does not return 
to normal after bronchodilator administration (Calverley and 
Walker). Unfortunately when applying the GOLD criteria 
in our group of obstructive lung disease patients 62% of the 
asthma patients fulﬁ  lled the diagnosis for COPD purely on 
spirometric grounds. It is a well known fact that a percent-
age of patients with chronic severe asthma have persistent 
airﬂ  ow obstruction (Bumbacea et al 2003).
In our study population, there was a signiﬁ  cantly greater 
improvement in FEF50 in the asthma group compared to the 
COPD group (Table 2). This sensitive parameter may be 
useful for long term studies in individuals when onset of 
disease is sought (Cochrane et al 1977). It is, however, not 
recommended for routine assessment of the BDR due to 
intra-individual variability (Knudson et al 1983).
Despite the inherent interdependence of FEV1 and FVC, 
we found a differential response of the FEV1/FVC ratio 
between the two groups (Figure 1). Due to a greater FEV1 
compared to FVC response in the asthma group (Table 2), 
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Figure 2 Bronchodilator response expressed as an increased percentage from initial FEV1
()  and as an increase percentage from the predicted FEV1
(     ). Horizontal bars 
indicate conﬁ  dence limits for means at 95% conﬁ  dence interval.International Journal of COPD 2008:3(4) 698
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the FEV1/FVC ratio signiﬁ  cantly (p = 0.003) increased in 
the asthma group, but remained low in the COPD group 
after bronchodilatation. On close examination of previously 
published results it is interesting to note that the FVC 
response appears to be generally greater than the FEV1 
response in COPD patients, but the inclusion criteria for 
these studies varied considerably, and no mention is made 
of the signiﬁ  cance of the differences observed (Calverley 
et al 2003; Newton et al 2002). The choice of lung function 
tests for a given purpose should take into consideration the 
degree of variability of that test if the interpretation is not to 
be misleading (McCarthy et al 1975). Tweeddale and col-
leagues (1987) found that the increase in FEV1 and FVC that 
excluded natural variability with 95% conﬁ  dence in patients 
with obstructive ventilatory defects was 160 mL and 330 mL 
respectively. Whether these values are applicable for both 
COPD and asthma was not speciﬁ  ed in that study. Despite 
this inherent difference between these two lung function 
parameters, the ATS guidelines suggest an increase after 
bronchodilator administration of more than 200 mL in either 
FEV1 or FVC to be signiﬁ  cant which may lead to diagnostic 
misclassiﬁ  cation (American Thoracic Society 1991).
The post-bronchodilator FEV1   80% predicted param-
eter has the disadvantage of requiring a set of predicted 
values applicable to a speciﬁ  c population group, making 
comparison of international studies difﬁ  cult. Using a ﬁ  xed 
percentage of the predicted value as the lower limit of normal 
can therefore result in inappropriate classiﬁ  cation of patients 
(Quedrelli et al 1999a).
Using a ﬁ  xed FEV1/FVC ratio as the lower limit of normal 
has recognized limitations (Knudson et al 1983; American 
Thoracic Society 1991). It has, however, been suggested 
by some authors to offer certain beneﬁ  ts as a compromise 
solution among competing deﬁ  nitions of obstruction, in that 
the ﬁ  xed ratio is easy to remember and does not require the 
use of population speciﬁ  c reference tables (Celli et al 2003). 
This assumption remains to be veriﬁ  ed in large population 
based studies. It cannot be emphasized enough that no single 
spirometric parameter or index will take the place of clinical 
evaluation in diagnosing patients with COPD or asthma, but 
spirometry is supplementary and remains the objective cor-
nerstone (Pauwels et al 2001). Agreement should be reached 
internationally on the spirometric evaluation of patients with 
obstructive lung disease. Different criteria used to deﬁ  ne 
obstruction and reversibility will result in vastly different 
prevalence rates of obstructive lung diseases in the general 
population and it complicates international comparisons of 
studies (Viegi et al 2000; Celli et al 2003). It is time that the 
appropriateness of deﬁ  nitions used to date is reconsidered.
The lung function data for each patient on our study can 
be seen as a snap shot and longitudinal reevaluation would 
have been ideal. Fluctuation in airway function is a well 
known fact, and it has to be taken into account in the evalu-
ation of patients that the lungs are a complex and dynamic 
system. Acute bronchodilator response has limited value 
in differentiating bronchial asthma from COPD (Chhabra 
2005). It does not help that the guidelines focuses on post 
bronchodilator FEV1 for COPD and pre bronchodilator 
values for asthma when it comes to classiﬁ  cation of disease 
severity (Sterk 2004).
In an attempt to keep the groups clinically diagnosed with 
COPD or asthma as “pure” as possible, we did not include 
asthmatic smokers, patients with known combined disease 
or patients with COPD in the absence of a strong smoking 
history. The selection criteria of COPD and asthma patients 
could therefore potentially be seen as artiﬁ  cial. All of these 
Table 3 Sensitivity, speciﬁ  city, predictive values and accuracy of each lung function criteria to diagnose COPD based on the bronchodilator 
response
Lung function
criteria
Cutoff
level
Sensitivity % Speciﬁ  city % Positive
predictive
value, %
Negative
predictive
value, %
Accuracy %
Post bronchodilator  70% and 80% 100 38 63 100 70
FEV1/FVC % and FEV1 
%pred
FEV1 %∆init and ∆ abs  12% and 200 mL 55 81 75 63 67
FEV1 %∆pred  9% 59 76 72 64 67
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity; %∆init, percentage change from initial; abs∆, absolute change; %∆pred, percentage 
change from predicted; % pred, percentage of predicted.International Journal of COPD 2008:3(4) 699
Bronchodilator responses in COPD and asthma
groups would warrant special attention in clinical practice, 
but for the purposes of the article it was impossible to 
include them.
In our study population the post-bronchodilator 
FEV1   80% predicted in combination with the FEV1/FVC 
ratio value  70% (criteria #1) was very sensitive (100%) in 
diagnosing COPD. Unfortunately the criteria were unable 
to distinguish reliably between patients with COPD and 
asthma as 62% of asthmatic patients did not achieve “nor-
mal” spirometry in the stage of obstructive lung disease 
studied here. The conventional BDR criteria (criteria #2 
FEV1   12% and absolute change  200 mL, criteria #3 
FEV1 change from predicted  9%) were speciﬁ  c, because 
a smaller percentage of asthma patients fell below the 
historically selected positive BDR response criteria, but it 
was less sensitive due to the positive BDR response in the 
COPD patients as well. It might be a good idea to combine 
the GOLD criteria (criteria #1) as well as the conventional 
BDR criteria (criteria #2) to increase the accuracy. In sum-
mary, asthmatic subjects show more reversibility than COPD 
subjects even when they have post-BD airﬂ  ow obstruction. 
Adding the bronchodilator test in the diagnoses of COPD 
(GOLD) guidelines could help to reduce the misclassiﬁ  ca-
tion of asthmatics with COPD.
In the evaluation of obstructive lung disease spirometry 
remains an investigative tool to conﬁ  rm a clinical suspicion. 
Additional meaningful outcome measures are urgently needed 
to accurately distinguish between COPD and asthma.
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